Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Operating Leases (2019 - 2025)

Historic Operating Leases for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to $1.9 million.

  • Coherus Oncology's Operating Leases fell 4792.61% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 4792.61%. This contributed to the annual value of $3.3 million for FY2024, which is 3832.58% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Operating Leases is $1.9 million, which was down 4792.61% from $2.4 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Operating Leases high stood at $9.2 million for Q1 2021, and its period low was $1.4 million during Q3 2023.
  • Its 5-year average for Operating Leases is $4.9 million, with a median of $4.7 million in 2024.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 7654.74% in 2023, then soared by 16023.68% in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's Operating Leases stood at $7.3 million in 2021, then crashed by 30.41% to $5.0 million in 2022, then rose by 5.59% to $5.3 million in 2023, then crashed by 38.33% to $3.3 million in 2024, then crashed by 40.78% to $1.9 million in 2025.
  • Its Operating Leases was $1.9 million in Q3 2025, compared to $2.4 million in Q2 2025 and $2.9 million in Q1 2025.